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OBJECTIVE — To assess whether prandial insulin, in addition to basal insulin, has an effect
on the rate of glucose appearance from a meal in people with type 1 diabetes.
RESEARCHDESIGNANDMETHODS — Therateofglucoseappearancefromamixed
meal (Rameal) was investigated in six adult (aged 24  2 years), lean (BMI 23.6  1.5 kg/m
2)
subjects with well-controlled type 1 diabetes (duration 7.9  6.9 years, A1C 7.6  0.9%)
with/without prandial insulin. Actrapid was infused to maintain euglycemia before meals were
consumed. Subjects consumed two identical meals on separate occasions, and Rameal was mea-
suredusingadualisotopemethod.[6,6-
2H2]glucosewasincorporatedintothemeal(0.081g/kg
body wt), and a primed constant/variable rate infusion of [1,2,3,4,5,6,6-
2H2]glucose was ad-
ministered. In the tests with prandial insulin, an additional bolus dose of Actrapid was given 20
min before the meal at 0.1 units/kg body wt.
RESULTS — Insulin concentration with prandial insulin was signiﬁcantly higher than during
basalinsulinstudies(11916vs.6615pmol/l,P0.03bypairedttest).Despitedifferences
in insulin concentration, there were no differences in total glucose appearance (3,398  197 vs.
3,307343mol/kg)ortimetakenfor25%(33.13.3vs.31.73.5min),50%(54.63.5
vs. 54.1  4.7 min), and 75% (82.9  7.1 vs. 82.8  5.8 min) of total glucose appearance. The
fraction of the glucose dose appearing in the circulation was the same for basal (73  8%) and
prandial (75  4%) study days.
CONCLUSIONS — These results suggest that meal glucose appearance is independent of
prandial insulin concentration in people with type 1 diabetes.
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P
lasma glucose concentration is de-
termined by several factors: the pro-
duction of glucose by the body, the
uptake of glucose by splanchnic and pe-
ripheral tissue, and the appearance of ex-
ogenous glucose from meals (1). Plasma
insulin regulates the production and up-
take of glucose (2,3), but its role in regu-
lating rates of glucose appearance from
meals (Rameal) is uncertain.
Rameal is determined by the rate at
which glucose is emptied from the stom-
ach and absorbed across the intestinal
membrane, and by the extent of extrac-
tionduringﬁrstpassoftheliverandother
splanchnic tissues, before reaching the
general circulation. The modiﬁcation by
insulinofanyoftheseprocesseswouldact
to regulate postprandial glucose levels
and would be an important consideration
forpeoplewithdiabetes.Inparticular,for
people with type 1 diabetes, the effect of
insulin on Rameal has important implica-
tions for the timings of prandial insulin
injections and the appropriateness of
pre-/post-meal insulin dosing.
Research in this area is limited and, al-
though there is some in vitro and in vivo
evidence that insulin plays a role in regulat-
ing glucose appearance in rats (4–6), these
ﬁndings have yet to be reproduced in hu-
man studies. In people with poorly con-
trolled type 1 diabetes, Rameal was normal
and unchanged with intensive insulin ther-
apy (7). However, these studies were de-
signed to investigate the effects of longer-
termhyperglycemia/insulindeﬁciency,and
the effect of acute insulin deﬁciency on
Rameal was not independently investigated.
No study to date has examined the
immediate independent effect of bolus
exogenous insulin administration on
Ramealinpeoplewithtype1diabetes.This
study therefore aimed to compare Rameal
in the presence of prandial insulin with
that measured at basal insulin concentra-
tions in people with type 1 diabetes.
RESEARCH DESIGN AND
METHODS— This study was ap-
proved by the Norfolk local research eth-
ics committee, and written informed
consent was obtained from each subject
beforeparticipation.Volunteerswithtype
1 diabetes were invited to the Medical Re-
search Council (MRC) Human Nutrition
Research (HNR) where their blood pres-
sure and hemoglobin were determined.
A1C levels were measured and subjects
excluded if they had elevated blood pres-
sure, anemia, or A1C 11%. Six lean
(BMI 23.6  1.5 kg/m
2) adult (24  2
years) subjects with well-controlled type
1diabetes(duration7.96.9years,A1C
7.6  0.9%) treated with multiple daily
injection (MDI) regimens were recruited.
All subjects participated in 2 study
days where their response to glucose in-
corporated into a solid meal (sweet pan-
cakes) was measured. Studies were
conducted at Addenbrooke’s Hospital
Wellcome Trust Clinical Research facility
(WTCRF). Subjects were admitted to the
WTCRF volunteer suite at 1800 h on the
evening before each study day, and two
cannulas were inserted into antecubital
veins: one for frequent blood sampling and
one for intravenous infusions. Subjects
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identical on each study visit, and took their
normal short-acting prandial insulin dose.
Subjects omitted their usual long-acting
evening insulin dose, and plasma glucose
levels were stabilized overnight using a
variable-rate intravenous insulin infusion
(Actrapid) based on the recommendation
of a model-predictive controller (8).
At 0600 h the next day, a primed (1
mg/kg) intravenous infusion of
[1,2,3,4,5,6,6-
2H2]glucose (0.1 mg  
kg
1   min
1) was begun and continued
for the duration of studies. As imple-
mentedbyotherinvestigators(9),inor-
der to minimize non–steady state errors
in calculating the endogenous glucose
production (EGP), changes in glucose
speciﬁc activity were reduced by main-
taining the ratio of tracer ([1,2,3,4,
5,6,6-
2H2]glucose) to tracee (endo-
genous glucose component) as constant
as possible. During studies at basal in-
sulin, where no change in EGP were an-
ticipated, the infusion rate of
[1,2,3,4,5,6,6-
2H2]glucose was main-
tained constant. In studies when an ad-
ditional bolus dose of insulin was
administered, EGP was anticipated to
vary and infusion rates were reduced
accordingly: 0–10 min, 100%; 10–20
min, 95%; 20–30 min, 80%; 30–40
min, 70%; 40–50 min, 45%; 50–60 min,
40%; 60–110 min, 35%; 110–140 min,
40%; 140–180 min, 45%; 180–240
min, 55%; 240–270 min, 65%; and
270–300 min, 70%. At 0700 h, the in-
travenous insulin infusion was ﬁxed at
the average rate required to maintain
euglycemia for the previous hour and
maintained constant for the remainder
of the study day.
At 0800 h on both study days, sub-
jects were given a meal (sweet pancakes)
with energy derived as 45% from carbo-
hydrate, 40% from fat, and 15% from
protein sources and contained 0.9 g glu-
cose/kg body wt. Meal size was adjusted
for body weight (8 kcal/kg body wt), and
[6,6
2H2]glucose was incorporated to re-
place 9% of meal glucose. Two baseline
blood samples were taken to establish
fasting glucose, insulin, and isotope con-
centrations, and subjects were then given
the meal. A further 22 blood samples (5
ml) were taken at 10, 20, 30, 40, 50, 60,
70, 80, 90, 100, 110, 120, 130, 140, 150,
165, 180, 195, 210, 240, 270, and 300
min. On basal insulin study days, no ad-
ditional insulin was given, but on pran-
dial insulin study days, a dose of Actrapid
was given 20 min before the meal (0.1
unit/kg body wt).
Analytical techniques
All blood samples were kept on ice before
plasma was separated by centrifugation
and subsequently kept at 80°C until
analysis was performed. Plasma insulin
wasmeasuredbya1235AutoDELFIAau-
tomatic immunoassay system using a
two-step time-resolved ﬂuorometric as-
say (kit no. B080-101; DAKO, Ely, Cam-
bridgeshire,U.K.)(coefﬁcientofvariation
2%) using the method previously de-
scribed (10). Plasma glucose concentra-
tion was determined from whole blood
samples immediately after each blood
sample was taken using a Yellow Springs
Instrument (Lynchford House, Farnbor-
ough,Hants,U.K.),and[6,6-
2H2]glucose
and [1,2,3,4,5,6,6-
2H2]glucose isotopic
enrichmentwasmeasuredinduplicateby
gas chromatography–mass spectrometry
usinganAgilent5973N(AgilentTechnol-
ogies, Workingham, U.K.).
Mathematical methods and
calculations
The method utilizing a two compartment
glucose model and the maximum likeli-
hood approach combined with a regular-
izationmethodwasusedforcalculationof
Rameal and EGP from the measured con-
centrations of glucose, [6,6-
2H2]glucose
and [1,2,3,4,5,6,6-
2H2]glucose (11).
The method, originally designed for
the triple tracer meal study design, was
adapted for the dual tracer study design.
Brieﬂy, the method assumes smoothness
of 1) the fractional glucose clearance, 2)
EGP, and 3)R a meal, whereas the tradi-
tional approaches assume smoothness of
the measured concentrations of native
glucose and tracer-to-tracee ratios (12).
The extent of smoothness is determined
by the SD of the measurement error for
native and tracer glucose. A two com-
partmental model of glucose kinetics
was assumed with population values for
model parameters identical across all
glucose species with k21  0.05/min,
Figure 1—Plasma insulin (A) and glucose (B) concentrations following a meal under conditions
of basal insulin and with an additional insulin bolus at 20 min.
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body wt (13), where k21 and k12 repre-
sent rate constants of glucose transfer
between plasma and interstitial glucose
compartments and V1 represents the
glucose volume of distribution.
Total glucose appearance was calcu-
latedfromtheareaunderthecurve(AUC)
of the glucose appearance/time proﬁles.
Time taken for 20, 50, and 75% of total
glucose appearance was calculated by as-
suming a linear proﬁle between appear-
ance rates at each time point. The fraction
of ingested glucose appearing in the cir-
culation was calculated as the ratio of
totalglucoseappearancetothedosesize
administered.
The total amount of glucose appear-
ing in the circulation on each study day
was compared using paired t tests, as was
thetimetakenfor25,50,and75%oftotal
glucoseappearancetotakeplace.Fractional
glucose appearance on prandial and basal
insulin study days were also compared by
paired t test. Results are presented as
means SEM (SD for baseline measure-
ments). Statistical signiﬁcance was declared
at P  0.05.
RESULTS
Baseline data
Before the meal was given, basal glucose
levels were not different on basal (IB) and
prandial (IP) study days (IP 5.5  0.5 vs.
IB 5.3  0.2 mmol/l, P  NS). As insulin
was administered 20 min before the meal
on prandial insulin study days, basal in-
sulin levels at time 0 were signiﬁcantly
elevatedonprandialstudydays(IP119
16 vs. IB 66  15 pmol/l, P  0.03).
Postprandial glucose, insulin,
Rameal, and EGP
Postprandial glucose, insulin, Rameal, and
EGP proﬁles are presented in Figs. 1 and
2.Onprandialcomparedwithbasalinsu-
lin study days, there were signiﬁcantly
higher AUC insulin and average insulin
concentrations, whereas AUC total glu-
cose concentrations were signiﬁcantly
lower (Table 1). There was no difference
in total glucose appearance (Table 1),
Rameal at any time point (Fig. 2A), or time
taken for 25, 50, and 75% of total glucose
appearance to take place (Table 1). The
fraction of the glucose dose appearing in
the circulation was the same under both
conditions and was, on average, 75  4%
and 73  8% (P  NS) under prandial
and basal conditions, respectively. There
was no signiﬁcant difference in total AUC
EGP on different study days, but different
patterns were evident (Fig. 2B).
CONCLUSIONS— The current work
shows that an exogenous dose of insulin,
givenbeforeameal,hadnosigniﬁcanteffect
on rates of glucose appearance or total frac-
tional glucose appearance in people with
type 1 diabetes.
Insulin and Rameal
Rat studies suggest that insulin may have
importanteffectsonintestinalglucoseab-
sorption (4–6). Conversely, a study of
dogs showed no effect of insulin on glu-
cose absorption (14), although direct ap-
plication of animal work to humans may
be unsuitable due to differences in the
physiology of glucose metabolism.
Figure 2—Rates of postprandial meal–derived glucose appearance (Rameal)( A) and EGP (B) fol-
lowing a meal under conditions of basal insulin and with an additional insulin bolus at 20 min.
Table 1—AUC and mean plasma insulin, AUC and mean plasma glucose, AUC Rameal, frac-
tionalglucoseappearance,andtimetakenfor25,50,and75%appearanceonbasalinsulin(IB)
and prandial insulin (IP) study days
IB IP P
AUC insulin (nmol/l per 300 min) 18.6  5.1 34.1  3.8 0.030
Mean insulin (pmol/l) 66  15 119  16 0.030
AUC glucose (mmol/l per 300 min) 3,351  104 2,625  124 0.004
Mean glucose (mmol/l) 10.9  0.3 8.2  0.6 0.004
AUC Rameal (mol/kg) 3,307  343 3,398  197 NS
Fractional appearance (%) 73  87 5  4N S
Time taken for glucose appearance (min)
25% dose 31.7  3.5 33.1  3.3 NS
50% dose 54.1  4.7 54.6  3.5 NS
75% dose 82.8  5.8 82.9  7.1 NS
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effect of hyperglycemia on meal glucose
appearance rate, showed that at plasma
glucose concentrations of 6 or 10 mmol/l,
Rameal was equivalent (15). Pehling et al.
(7) investigated rates of glucose appear-
ance in healthy subjects and those with
poorly controlled type 1 diabetes and
subsequently restudied those with type 1
diabetes during intensive insulin therapy.
Despiteinsulindeﬁciencyandfastingand
postprandial hyperglycemia, people with
untreated diabetes showed no difference
in Rameal compared with healthy individ-
uals (7), and following intensive insulin
therapy, there was similarly no difference
in rates of meal glucose appearance.
These studies are in agreement with the
current work, where insulin and glucose
levelsdidnotappeartoaffectratesofmeal
glucose appearance.
IfRamealisconsideredtorepresentthe
sumofprocessesofgastricemptying,glu-
cose absorption, and ﬁrst pass splanchnic
extraction, then although counterbalanc-
ing changes in these processes cannot be
ruled out, it seems likely that all three
were not affected by plasma insulin con-
centration. The lack of effect on ﬁrst pass
splanchnic extraction may be surprising.
Insulin exerts large effects on peripheral
glucose uptake into muscle and adipose
tissue (16), and a similar function in
splanchnictissuesmightbeexpected.The
mode of glucose transport, predomi-
nately via GLUT4 into peripheral tissue
and GLUT2 into splanchnic tissue, can
explain this difference. GLUT4 is insulin
regulated,whileGLUT2isalmostentirely
regulated by, and directly proportional
to, plasma glucose concentration (3); the
absence of an effect by insulin may there-
fore be expected.
Fractional systemic glucose
appearance
The fractional appearance of meal-
derived glucose can be determined by the
percentage of ingested glucose that ap-
pears in the circulation. In the current
work, fractional glucose appearance was,
on average, 74  4% (IB 73  8 vs. IP
75  4%, P  NS). The difference be-
tween glucose ingested and that appear-
ing in the systemic circulation may be
accounted for by retention in the small
intestine, fermentation to lactate, and
splanchnic tissue and liver extraction on
ﬁrst pass into the general circulation. The
contribution of glucose fermentation to
lactate is thought to be small (17), but
direct arterio-hepatic-venous difference
experimentshaveshownﬁrstpasshepatic
glucose extraction to be important and to
be responsible for extracting 5–8% of
the ingested dose (18).
Despite this, far lower values and
large variations in fractional glucose ap-
pearance have been observed by investi-
gators working in different laboratories.
The review by Livesey et al. (19) suggests
that fractional appearance of glucose fol-
lowingoralglucoseadministrationranges
from 65 to 104% in healthy adults and
people with type 1 or type 2 diabetes.
Thereappearstobesystematicdifferences
in measurement, since errors reported in
individual studies are reasonably small
compared with the range of mean values
obtained.
Although some investigators suggest
that differences can be accounted for by
retention in the intestinal lumen and ﬁrst
pass hepatic extraction (15), others argue
that discrepancies are due to errors in
modeling methods used. In the current
work, a two-compartmental model is ap-
plied to the dual isotope approach with
assumed values for model kinetic param-
eters. A two-compartmental model has
been shown to improve estimates of
Rameal (19) compared with Steele’s one-
compartmental model (20) and, assum-
ing population values for rate constants,
simpliﬁes further calculation of Rameal.
More recently, however, investigators ar-
gue that the dual isotope method is inad-
equate and that three tracers are needed
for accurate estimation of Rameal (21).
During these comparative studies, al-
though the dual-tracer method appeared
to underestimate overall systemic glucose
appearance (16% lower), proﬁles for
dual- and triple-tracer techniques were
very similar (21), and it may be consid-
ered that a two-compartmental dual iso-
tope approach is acceptable.
Incomplete absorption could also ex-
plain the lower rates of fractional appear-
ance. Nearly complete absorption has
been estimated over 3.5 h following an
oral glucose load (19), but following glu-
cose given as part of a mixed meal, 5h
was necessary for complete glucose ab-
sorption (7). In the current work, mea-
surements were made for only 5 h, but
due to the composition of the meal (car-
bohydrate in the form of pure glucose),
glucose was likely to have been absorbed
more rapidly. Indeed, from the average
Rameal proﬁles (Fig. 2A) it appears that
absorption was ﬁnished, and incomplete
absorption seems unlikely to have been
an issue.
From studies reviewed by Livesey et
al. (19), there is no difference between
average values for fractional appearance
ratesinhealthypeople(80.63.1%)and
those with impaired glucose tolerance/
type 2 diabetes (85  2.3%, P  0.31).
Only one study investigated total appear-
ance in subjects with type 1 diabetes, and
the estimate of 93% (7) is well within
the range of that observed in healthy
individuals. There appears to be no ev-
idence that the fraction of glucose ap-
pearing in the systemic circulation is
affected in type 1 diabetes, and this is
supported by the current work, where
typical values were obtained.
Exogenous insulin affects not only
plasma insulin concentrations but also
plasma glucose levels. Since insulin and
glucose levels changed simultaneously in
opposite directions in the current work
(increased insulin but reduced glucose
concentrations),itmaybespeculatedthat
they acted in opposite directions and, by
counterbalancing one another, Rameal re-
mained unchanged. Despite this possibil-
ity, the current work still gives evidence
for the overall impact of a bolus dose of
insulin:Ramealandtotalfractionalappear-
ance are independent of exogenous insu-
lin administration in people with type 1
diabetes.
In conclusion, the present study sug-
gests that, in people with type 1 diabetes,
exogenous insulin administration does
not affect postprandial Rameal or the frac-
tion of glucose appearing in the circula-
tion. The injection of an insulin dose
before or after a meal, in contrast to its
affect on glucose utilization, would not
affect the rate of glucose appearance.
These ﬁndings provide important infor-
mation for people with type 1 diabetes
when considering the size and timing of
meal-time insulin doses.
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